Rubicon Research Limited reported a strong financial performance for the quarter and year ended March 31, 2026 (FY26), with net profit for the quarter rising 112% to ₹768 million from ₹362 million in the corresponding period of the previous year. Revenue from operations for Q4FY26 increased 44% to ₹5.14 billion compared to ₹3.58 billion in Q4FY25, driven by robust growth across its pharmaceutical product portfolio. For the full year FY26, net profit rose 84% to ₹2.47 billion and revenue increased 37% to ₹17.54 billion. The Board has recommended a final dividend of ₹1.50 per equity share, subject to shareholder approval.

Key Financial Highlights

The company's audited consolidated financial results for FY26 demonstrated significant improvement across major metrics. Earnings per share (EPS) for the year increased to ₹15.52 from ₹8.82 in the prior year. The statutory auditors, M/s. Deloitte Haskins & Sells LLP, issued an audit report with an unmodified opinion on the financial results.

Operational and Strategic Developments

Revenue growth was broad-based, with the top 5 products contributing 39% of revenue in Q4FY26 compared to 34% in Q1FY26. USD revenue for Q4FY26 stood at $56 million, up 35% year-on-year, with approximately 98% of total revenue being USD denominated. Specialty products contributed 32.8% to gross profit for the quarter. The company received 12 product approvals in FY26, and 24 products were under review by the USFDA as of March 31, 2026.

Management noted that while gross margins contracted slightly sequentially to 66.3% due to reliance on outsourced manufacturing, Operating EBITDA margin sustained in the 22-23% range. The Pithampur site has been qualified and filed with the USFDA, with production ramp-up expected in Q1 CY27. The company also completed an Initial Public Offering (IPO) during the year, aggregating to ₹13.78 billion, with shares listed on the NSE and BSE on October 16, 2025.

Rubicon Research Limited’s board has approved the formulation and adoption of the Employees Stock Option Scheme 2026. The scheme authorizes the grant of stock options aggregating 24,84,415, corresponding to an equal number of equity shares of INR 1 each, to eligible employees of the company and its subsidiaries. This approval, granted on May 29, 2026, is subject to the approval of shareholders and other regulatory or statutory approvals.

The new scheme is in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The total pool of options includes 6,72,162 balance options available under the existing Scheme 2022. The board has the authority to grant these options in one or more tranches.

The exercise price of the stock options will not be less than the face value of the equity shares of the company. Specific details regarding the time within which the options may be exercised and other significant terms will be disclosed at the time of seeking shareholder approval.

Key Details of ESOS 2026

The board meeting commenced at 02:30 PM IST and concluded at 4:10 PM IST on May 29, 2026. Deepashree Tanksale, Company Secretary, confirmed the outcome in the regulatory filing.